Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 12/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10708676 | 0.89 | CCR2 (0.39) | CCR2HTTL3MBTL1 | |
| SCHEMBL10709204 | 0.87 | CCR2 (0.39) | CCR2HTT | |
| SCHEMBL2997778 | 0.86 | — | — | |
| SCHEMBL8450270 | 0.84 | CCR2 (0.42) | CCR2HTTL3MBTL1RAB9A | |
| SCHEMBL10706616 | 0.82 | HTT (0.38) | CCR2HTT | |
| SCHEMBL5789345 | 0.82 | HTT (0.38) | CCR2HTT | |
| SCHEMBL1423856 | 0.81 | HTT (0.44) | CCR2HTT | |
| SCHEMBL28018713 | 0.81 | CCR2 (0.41) | CCR2HTTL3MBTL1 | |
| SCHEMBL31060569 | 0.80 | CCR2 (0.42) | CCR2HTT | |
| SCHEMBL18289450 | 0.79 | HTT (0.41) | CCR2HTTL3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0124274-B1 | ELECTRON BEAM SENSITIVE MIXTURE RESIST | GAF CORPORATION (US) | 1988-06-22 | — | — | EP | claimed |
| US-4375398-A | CROSSLINKING, VINYL ETHER | GAF CORPORATION (US) | 1983-03-01 | — | — | US | claimed |
| US-20100222349-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| US-20100184770-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-07-22 | — | — | US | disclosed |
| EP-2205585-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | Glaxo Group Limited (GB) | 2010-07-14 | — | — | EP | disclosed |
| EP-2091538-B1 | 4-BENZYL-1(2H)-PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-03-03 | — | — | EP | disclosed |
| WO-2009050204-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
| EP-0124274-B1 | ELECTRON BEAM SENSITIVE MIXTURE RESIST | GAF CORPORATION (US) | 1988-06-22 | — | — | EP | disclosed |
| EP-0124274-A2 | Electron beam sensitive mixture resist | GAF CORPORATION (US) | 1984-11-07 | — | — | EP | disclosed |
| EP-0088977-A2 | Electron beam sensitive resist | GAF CORPORATION (US) | 1983-09-21 | — | — | EP | disclosed |
| US-4375398-A | CROSSLINKING, VINYL ETHER | GAF CORPORATION (US) | 1983-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184770-A1 | COMPOUNDS | CMA1, TSLP, IL5 | CCR2 648/4885HTT 1450/4885L3MBTL1 4882/4885 |
| US-20100222349-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | IL5, HRH2, HRH1 | CCR2 356/4885HTT 1034/4885L3MBTL1 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.